Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 1998

View Archived Issues

Evaluation of the analgesic potential of 1,2,6-IP3

Recombinant methioninase shows clinical efficacy in depleting serum methionine

Neurocrine Biosciences reveals new technology

Evaluation of anti-IgE therapy in patients with seasonal allergic rhinitis

The Liposome Company: FY 1997 highlights

Sponge-derived natural product shows promise as a new cancer therapeutic

Muscarinic cholinergic agents from American Home

Pharmacyclics: Q2 1998 highlights

CoCensys: Q4 and FY 1997 highlights

First corticosteroid dry powder inhaler launched in the U.S.

Floxin Otic launched in U.S.

CellPro to begin clinical evaluation of B-Cell Depletion System

Celgene: Q4 and year-end 1997 highlights

CPMP recommends European approval of Exelon

Termination of merger discussions between SKB and Glaxo Wellcome

Perkin-Elmer and PerSeptive Biosystems complete merger

Flobufen update

Positive phase I results reported for TCAR product for MS

New herpes collaboration between Astra and Medivir

Apollo licenses technologies from U. of Florida

Quinolone HIV integrase inhibitors prepared at Warner-Lambert

First potent and selective CB2 receptor antagonist developed at Sanofi

DBD meets with FDA to discuss dibromodulcitol progress

Abbott will market Orion's calcium sensitizer levosimendan

Diatide issued approvable letter for AcuTect by FDA

Diversa receives NCI grant for pharmaceutical research

PI-88 one step closer to clinical testing

UCSF receives green light to develop new breast cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.